Mass Spectral Fingerprinting in Lung Cancer

Exhaled Breath Analysis by Secondary Electrospray Ionization - Mass Spectrometry (SESI-MS) in Patients With Lung Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02781857

Enrollment

309

Registered

2016-05-25

Start date

2016-05-01

Completion date

2024-03-06

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Keywords

Exhaled Breath, Mass Spectrometry, Fingerprinting

Brief summary

To answer the question whether a disease specific profile of breath in patients with lung cancer can be detected by an untargeted metabolomic study using exhaled breath analysis by mass spectrometry.

Interventions

OTHERNo intervention

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Confirmed lung cancer based on cytological or histological analysis. * Group A: any type of lung cancer eligible for surgical resection (up to TNM stage IIIa). * Group B: any type of lung cancer (small-cell carcinoma, non-small-cell carcinoma) not amenable for surgical resection. * Group C: matched controls. * Age between 18 and 85 years at study entry

Exclusion criteria

* Another 'active' secondary malignant disease (e.g. breast cancer, colon carcinoma) in group A and B, presence of any active malignant disease in group C (based on personal information). * Acute inflammatory disease (e.g. common cold) within the last 4 weeks. * Any other acute lung disease which affects breath measurements * Acute or chronic hepatic disease. * Renal failure or renal replacement therapy.

Design outcomes

Primary

Measure	Time frame	Description
Concentration of volatile organic compounds (VOCs) in the exhaled breath will be analysed using mass spectrometry	1 day, single measurement	The primary outcome will be the lung cancer specific mass spectrometric profile of VOCs of exhaled breath analysis (markers of lung cancer in exhaled breath).

Secondary

Measure	Time frame	Description
Group A: Concentration of volatile organic compounds (VOCs) in the exhaled breath will be analysed using mass spectrometry before and after lung cancer surgery	Group A: 2 measurements on 2 different days; Day 1: 1. measurement (before surgery), Day 2: (6-12 weeks after surgery): 2. measurement	The acquired profiles of mass spectral VOCs before and after lung cancer surgery will be analysed for significant differences.

Countries

Switzerland

Contacts

PRINCIPAL_INVESTIGATORMalcolm Kohler, Prof. MD

University of Zurich

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 8, 2026